International Journal of Head and Neck Surgery

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2023)
Volume  13 (2022)
Volume  12 (2021)
Volume  11 (2020)
Volume  10 (2019)
Volume  9 (2018)
Volume  8 (2017)
Volume  7 (2016)
Volume  6 (2015)
Volume  5 (2014)
Volume  4 (2013)
Volume  3 (2012)
Volume  2 (2011)
Volume  1 (2010)
Related articles

VOLUME 5 , ISSUE 1 ( January-April, 2014 ) > List of Articles

REVIEW ARTICLE

Utilization of Saliva as a Diagnostic Fluid in Determination of Oral Cancer

Sonal Pratapsingh Vahanwala, Soumyo Mukherji

Citation Information : Vahanwala SP, Mukherji S. Utilization of Saliva as a Diagnostic Fluid in Determination of Oral Cancer. Int J Head Neck Surg 2014; 5 (1):15-21.

DOI: 10.5005/jp-journals-10001-1172

Published Online: 01-06-2015

Copyright Statement:  Copyright © 2014; The Author(s).


Abstract

How to cite this article

Vahanwala SP, Mukherji S. Utilization of Saliva as a Diagnostic Fluid in Determination of Oral Cancer. Int J Head Neck Surg 2014;5(1):15-21.

PDF Share
  1. World Health Organization; Geneva 1992.
  2. Cancer Facts and Figures 2007. Atlanta: American Cancer Society 2007.
  3. Globocan 2000, cancer incidence, mortality and prevalence worldwide, Version 1.0. Lyon: IARC Press; 2001.
  4. Exploring the reasons for delay in treatment of oral cancer. Am Dent Assoc 2008;139:1346-1352.
  5. Biologic markers, cellular differentiation and metastatic head and neck cancer. Eur Arch Otorhinolaryngol 1993;250: 424-428.
  6. Carcinogenesis, markers, staging and prognosis of head and neck cancer. Curr Opin Oncol 1993;5:483-490.
  7. Emerging molecular markers of cancer. Nat Rev Cancer 2002;3:210-219.
  8. Screening for cancer of the head and neck: Addressing the problem. Surg Oncol Clin N Am 1999;8: 725-734.
  9. Diagnostic aids in the screening of oral cancer. Head Neck Oncol 2009;30:1-5.
  10. Analysis of new diagnostic methods in suspicious lesions of the oral mucosa. Med Oral Patol Oral Cir Buccal 2009;14:E210.
  11. Symptoms in early head and neck cancer: An inadequate indicator. Otolaryngol Head Neck Surg 1998;118:463-467.
  12. Evaluation and monitoring of screening program. Luxembourg: Office for the Official Publication of the European Communities 2001;243-254.
  13. Reproducibility of an oral cancer and precancer detection program using a primary health care model in Sri Lanka. Cancer Detect Prev 1991;15:331-334.
  14. Practical considerations for the establishment of an oral cancer screening programme. Commun Dent Health 1993;10(Suppl 1):79-85.
  15. Reliability of toluidine application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:535-540.
  16. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res 2005;65:8017-8021.
  17. Computer-assisted analysis of oral brush biopsies at an oral cancer screening program. J Am Dent Assoc 2002;133: 357-362.
  18. Oral cytology revisited. J Oral Pathol Med 2009;38:161-166.
  19. Clinical evaluation of chemiluminescent lighting: An adjunct for oral mucosal examinations. J Clin Dent 2006;17:59-63.
  20. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and tolouidine blue. Oral Oncol 2008;44:538-544.
  21. Fluorescence photography as a diagnostic method for oral cancer. Cancer Lett 1996;108:61-66.
  22. Screening programmes for the early detection and prevention of oral cancer. Aust Dent J 2009;54:170-172.
  23. Evaluation of screening strategies for improving oral cancer mortality: A cohrane systematic review. J Dent Educ 2005;69:255-265.
  24. The multistep nature of cancer development. Cancer Res 1984;44:4217-4223.
  25. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med 2009;29:71-85.
  26. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: A preliminary study. Clin Cancer Res 2000;6:2363-2370.
  27. Quantification of free RNA in serum and bronchial lavage: A new diagnostic tool in lung cancer detection? Lung Cancer 2005;48:145-147.
  28. Circulating RNA as a tumor marker: Detection of 5T4 mRNA in breast and lung cancer patient serum. Ann NY Acad Sci 2001;945:172-178.
  29. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep 2001;8:115-118.
  30. Isolation and comparative study of cell-free nucleic acids from human urine. Ann NY Acad Sci 2006;1075:334-344.
  31. Identification of cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009; 35:33-40.
  32. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:929-935.
  33. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004;10:8442-8450.
  34. Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients. Int J Cancer 2008; 123:594-600.
  35. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002;48: 1186-1193.
  36. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 2008;41:1191-1198.
  37. Squamous cell carcinomaantigen messenger RNA level in peripheral blood predicts recurrence after resection in patients with esophageal squamous cell carcinoma. Surgery 2006;139:678-685.
  38. Serum metastases mRNA is an important survival predictor in breast cancer. Br J Biomed Sci 2008;65:90-94.
  39. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007;97:964-970.
  40. Increased expression of PSA mRNA during brachytherapy in peripheral blood of patients with prostate cancer. Urology 2002;60:270-275.
  41. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: With special reference to neoadjuvant hormonal therapy. Urol Res 1999;27:291-296.
  42. The functions of saliva. J Dent Res 1987;66:623-627.
  43. Salivary flow in health and disease. Compend Suppl 1989;13:S461-469.
  44. The diagnostic applications of saliva: A review. Crit Rev Oral Biol Med 2002;13:197-212.
  45. Saliva as a diagnostic fluid. Oral Dis 2002;8:69-76.
  46. Saliva as a diagnostic fluid. Br Med J 1992;8: 207-208.
  47. Saliva as a diagnostic fluid. Int Dent J 2007;57: 295-299.
  48. Salivary enhancement therapies. Caries Res 2004;38: 241-246.
  49. Effects of gustatory stimulants of salivary secretion on salivary pH and flow: A randomized controlled trial. Oral Dis 2009;15:220-228.
  50. Methods for collecting saliva. Ann NY Acad Sci 1993;8:72-77.
  51. Oral fluid testing for drugs of abuse. Clin Chem 2009;55:1910-1931.
  52. Saliva as a diagnostic medium. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:103-110.
  53. Outcomes of blood and oral fluid rapid HIV testing: A literature review, 2000-2006. AIDS Patient Care STDS 2007;21:621-637.
  54. Proteomic diagnosis of Sjögren's syndrome. Expert Rev Proteomics 2007;4:757-767.
  55. The use of whole saliva in the differential diagnosis of Sjögren's syndrome. Adv Dent Res 1996;10:17-24.
  56. Salivary mRNA targets for cancer diagnostics. Oral Oncol 2008;44:425-429.
  57. Salivary and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990;8:701-704.
  58. The diagnostic applications of saliva: A review. Crit Rev Oral Biol Med 2002;13:197-212.
  59. Principles of saliva secretion. Ann NY Acad Sci 1993; 694:17-23.
  60. Application of saliva for drug monitoring: An in vivo model for transmembrane transport. Eur J Clin Chem Clin Biochem 1996;34:171-191.
  61. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005;150:119-131.
  62. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res 2000;260:248-256.
  63. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001;47:1488-1489.
  64. Membrane-derived microvesicles: Important and underappreciated mediators of cell-to-cell communication. Leukemia 2006;20:1487-1495.
  65. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009;6:267-283.
  66. Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 2008;14:1424-1432.
  67. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One 2009;4:e4722.
  68. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10: 1470-1476.
  69. Proteomic profiling of exosomes: current perspectives. Proteomics 2008;8:4083-4099.
  70. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009;8:2014-2018.
  71. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009;22:61-69.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.